Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy

Authors:

Abstract
Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC‐derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC‐derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti‐tumor activity and produced in essentially unlimited numbers. Stem Cells 2018;36:134–145
Funding Information
  • California Institute for Regenerative Medicine (DISC2-09615)
  • National Cancer Institute (R01CA203348, U01CA217885)

This publication has 167 references indexed in Scilit: